These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17635371)

  • 61. A pharmacokinetic model for alpha interferon administered subcutaneously.
    Chatelut E; Rostaing L; Grégoire N; Payen JL; Pujol A; Izopet J; Houin G; Canal P
    Br J Clin Pharmacol; 1999 Apr; 47(4):365-71. PubMed ID: 10233199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Scintigraphic study of radiolabelled interferon-alpha in osteosarcoma patients.
    Diez RA; Perdereau B; Peter M; Dorval T; Gongora R; Falcoff ET
    Clin Pharmacokinet; 1990 Jan; 18(1):82-9. PubMed ID: 2311332
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Commentary: 2B or 2A, that is the question.
    Hui DS; Lee R
    J Thorac Cardiovasc Surg; 2022 Jul; 164(1):e33. PubMed ID: 30857817
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV: interpretation of results and future prospects.
    Khedmat H; Taheri S
    Hepat Mon; 2010; 10(3):235-6. PubMed ID: 22308145
    [No Abstract]   [Full Text] [Related]  

  • 65. Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.
    Green JL; Osterhout RE; Klova AL; Merkwirth C; McDonnell SRP; Zavareh RB; Fuchs BC; Kamal A; Jakobsen JS
    Mol Ther Oncolytics; 2021 Dec; 23():547-559. PubMed ID: 34938855
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment.
    Ottesen JT; Pedersen RK; Dam MJB; Knudsen TA; Skov V; Kjær L; Andersen M
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751766
    [TBL] [Abstract][Full Text] [Related]  

  • 67. From Synthesis to Characterization of Site-Selective PEGylated Proteins.
    Belén LH; Rangel-Yagui CO; Beltrán Lissabet JF; Effer B; Lee-Estevez M; Pessoa A; Castillo RL; Farías JG
    Front Pharmacol; 2019; 10():1450. PubMed ID: 31920645
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
    García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
    BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ophthalmological side effects of interferon therapy of chronic hepatitis C.
    Medhat E; Esmat G; Hamza E; Abdel Aziz A; Fouad Fathalah W; Darweesh SK; Zakaria Z; Mostafa S
    Hepatobiliary Surg Nutr; 2016 Jun; 5(3):209-16. PubMed ID: 27275462
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PharmGKB summary: peginterferon-α pathway.
    Shuldiner SR; Gong L; Muir AJ; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Sep; 25(9):465-74. PubMed ID: 26111151
    [No Abstract]   [Full Text] [Related]  

  • 71. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
    de Kanter CT; Drenth JP; Arends JE; Reesink HW; van der Valk M; de Knegt RJ; Burger DM
    Clin Pharmacokinet; 2014 May; 53(5):409-27. PubMed ID: 24723109
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
    Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials.
    Yang Z; Zhuang L; Yang L; Chen X
    Gastroenterol Res Pract; 2013; 2013():739029. PubMed ID: 23662098
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
    BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
    Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
    Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
    García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
    BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.
    François C; Coulouarn C; Descamps V; Castelain S; Brochot E; Baron A; Duchaussoy I; Capron D; Nguyen-Khac E; Duverlie G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):903-8. PubMed ID: 22123700
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
    Singal AK; Jampana SC; Anand BS
    Dig Dis Sci; 2011 Aug; 56(8):2221-6. PubMed ID: 21643737
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Peginterferon and ribavirin treatment for hepatitis C virus infection.
    Tsubota A; Fujise K; Namiki Y; Tada N
    World J Gastroenterol; 2011 Jan; 17(4):419-32. PubMed ID: 21274371
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.